程晓波,邹佳,王春玲,王宇,杨强,邓意辉
CHENG Xiao-bo,ZOU Jia,WANG Chun-ling,WANG Yu,YANG Qiang,DENG Yi-hui*(School of Pharmacy

• 1:沈阳药科大学药学院

摘要(Abstract)：

目的研究不同粒径辅酶Q10乳剂和脂质体小鼠药物动力学和组织分布。方法以市售辅酶Q10注射液(S)为对照,考察其60 nm乳剂(E60)、120 nm乳剂(E120)、60 nm脂质体(L60)和120nm脂质体(L120)小鼠尾静脉给药后的药物动力学及组织分布特征;采用DAS2.1.1药物动力学软件,进行房室模型和统计矩两种模式拟合;以组织相对摄取率(re)为指标,评价载体的粒径和种类对组织靶向性的影响。结果不同粒径辅酶Q10乳剂和脂质体体内分布均符合双隔室模型;E60、E120、L60和L120的统计矩AUC分别是S组的1.17、1.50、5.99和8.65倍;re结果显示,E60组在心、脾和脑的含量分别是S组的2.64、2.74和1.95倍,E120组在心、脾和脑的含量分别是S组的4.89、3.77和2.38倍;L60组在脑中的含量是S组的1.56倍,L120组在脑和肺的含量分布是S组的2.28和1.85倍。结论载体粒径和种类对辅酶Q10体内分布的影响十分明显,市售注射液组、乳剂组和脂质体组的AUC依次增大,且同一载体中,120 nm组较60 nm组的AUC高;相对市售注射液,乳剂组对心、脾和脑有一定的靶向性,而脂质体组主要靶向于脑和肺,同一载体内,120 nm组在多数组织的富集量多于60 nm组。
Objective To study the pharmacokinetics and tissue distribution of CoQ10 emulsions and CoQ10 liposomes with different particle sizes in mice.Methods The commercial CoQ10 injection was used as a reference to investigate the pharmacokinetics and tissue distribution of CoQ10 emulsions and liposomes with different particle sizes given intravenous injection.All data were analyzed with compartment model and statistical moment respectively,using DAS software.Furthermore,the relative tissue exposure values(re) were utilized as an indicator to evaluate the effect of particle sizes and the type of carriers on the tissue targeting.Results The pharmacokinetic processes of CoQ10 emulsions and CoQ10 liposomes conformed to two compartmental models.The AUC calculated by statistical moment of E60,E120,L60,L120 was 1.17,1.50,5.99 and 8.65 times of the control group respectively.The re of E60 group in heart,spleen and brain was 2.64,2.74 and 1.95 times over that of S group,but E120 group was 4.89,3.77 and 2.38 respectively.The level of L60 in brain was 1.56 times compared with S group,while the distributions of L120 in brain and lung were 2.28 and 1.85 times up on that of S group.Conclusions Particle sizes and types of carriers had a significant effect on the biodistribution of CoQ10.In rank order for AUC we find the least from commercial injections,then the emulsions,and the greatest from liposomes.For the same carrier,the AUC of 120nm group was higher than 60nm group.Comparing with commercial injections,emulsions were targeted to heart,spleen and brain,while liposomes were brain and lung.Moreover,the retained levels of 120 nm groups in tissues were more than 60 nm for the same carrier.

关键词(KeyWords)： 粒径;辅酶Q10;乳剂;脂质体;药物动力学;组织分布
size;CoQ10;emulsions;liposomes;pharmacokinetics;tissue distribution

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 程晓波,邹佳,王春玲,王宇,杨强,邓意辉
CHENG Xiao-bo,ZOU Jia,WANG Chun-ling,WANG Yu,YANG Qiang,DENG Yi-hui*(School of Pharmacy

DOI: 10.14066/j.cnki.cn21-1349/r.2013.08.014

参考文献(References)：

• [1]BHAGAVAN H N,CAUPRA R K.Coenzyme Q10:absorption,tissue uptake,metabolism and pharmacoki-netics[J].Free Radic Res,2006,40(5):445-453.
• [2]DHANASEKARAN M,REN Jun.The emerging roleof coenzyme Q10 in aging,neurodegeneration,cardio-vascular disease,cancer and diabetes mellitus[J].CurrNeurovasc Res,2005,2(5):447-459.
• [3]OVERVAD K,DIAMANT B,HOL M L,et al.Coen-zyme Q10 in health and disease[J].Eur J Clin Nutr,1999,53(10):764-770.
• [4]TURUNEN M,OLSSON J,DALLNER G.Metabo-lism and function of coenzyme Q[J].Biochem Bio-phys Acta,2004,1660(1),171-199.
• [5]LANGSOEN P H,LANGSJOEN A M.Overview ofthe use of CoQ10 in cardiovascular disease[J].Bio-Factors,1999,9(2):273-284.
• [6]CONKLIN K A.CoQ10 for prevention of anthracy-cline-induced cardiotoxicity[J].Integr Cancer Ther,2005,4(2):110-130.
• [7]易德平,田治科,侯国枝,等.辅酶Q10制剂新技术研究进展[J].中国药业,2007,16(22):23-25
• [8]YU H Y,LIU R F.Hepatic uptake and tissue distribu-tion of liposomes:influence of vesicle size[J].DrugDev Ind Pharm,1994,20(4):557-574.
• [9]周卫,平其能,王丽杰,等.羟喜树碱脂质体的粒径对组织分布的影响[J].中国药科大学学报,2005,36(2):125-128.
• [10]方超,施斌,洪鸣凰,等.粒径和MePEG相对分子质量对隐形纳米粒体外巨噬细胞吞噬和大鼠体内长循环的影响[J].药学学报,2006,41(4):305-312.
• [11]孙维彤,邹伟伟,李爱国,等.脂质体粒径对促进托氟啶口服吸收的影响[J].山东大学学报(医学版),2007,45(6):639-645.
• [12]李春雷,张兰,王彩霞,等.粒径对米托蒽醌脂质体疗效及毒性的影响[J].河北医科大学学报,2008,29(4):555-556.
• [13]UCHIYAMA K,NAGAYASU A,YAMAGIWA Y,etal.Effects of the size and fluidity of liposomes ontheir accumulation in tumors:A presumption of theirinteraction with tumors[J].Inter J of Pharmaceutics,1995,121(2):195-203.
• [14]NAGAYASU A,UCAIYAMA K,KIWADA H.Thesize of liposomes:a factor which affects their targetingefficiency to tumors and therapeutic activity of liposo-mal antitumor drugs[J].Advanced Drug Delivery Re-views,1999,40(1):75-87.
• [15]AWASTHI V,GARCIA D,GOINS B,et al.Circulationand biodistribution profiles of long-circulating PEG-lipo-somes of various sizes in rabbits[J].Inter J of Pharma-ceutics,2003,253(1):121-132.
• [16]CHARROIS G J,ALLEN T M.Rate of biodistributionof STEALTHRliposomes to tumor and skin:influ-ence of liposome diameter and implications for toxici-ty and therapeutic activity[J].Biochimica et Biophys-ica Acta,2003,1609(1):102-108.
• [17]MAYER L D,CULLIS P R,BALLY M B.Influenceof vesicle size,lipid procomposition,and drug-to-lipidratio on the biological activity reliposomal doxorubicinin mice[J].Cancer Res,1989,49:5922-5930.
• [18]CRANE F L.Biochemical functions of coenzyme Q10[J].J AM Coll Nutr,2001,20(6):591-598.
• [19]龚茜玲.人体解剖生理学[M].北京:人民卫生出版社,1999:75.